A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC)

被引：0
|
作者：
Angevin, E.
Gruenwald, V.
Ravaud, A.
Castellano, D. E.
Lin, C. C.
Gschwend, J. E.
Harzstark, A. L.
Chang, J.
Wang, Y.
Shi, M. M.
Escudier, B. J.
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Hannover Med Sch, D-30623 Hannover, Germany
[3] Hop St Andre CHU, Bordeaux, France
[4] Hosp Univ 12 Octubre, Madrid, Spain
[5] Natl Taiwan Univ Hosp, Taipei, Taiwan
[6] Tech Univ Munich, D-80290 Munich, Germany
[7] Univ Calif San Francisco, San Francisco, CA 94143 USA
[8] Novartis Pharmaceut, E Hanover, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4551
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors
    Sarker, Debashis
    Molife, Rhoda
    Evans, T. R. Jeffrey
    Hardie, Maryon
    Marriott, Cheryl
    Butzberger-Zimmerli, Priska
    Morrison, Rosemary
    Fox, Judith A.
    Heise, Carla
    Louie, Sharianne
    Aziz, Natasha
    Garzon, Felix
    Michelson, Glenn
    Judson, Ian R.
    Jadayel, Dalal
    Braendle, Edgar
    de Bono, Johann S.
    CLINICAL CANCER RESEARCH, 2008, 14 (07) : 2075 - 2081
  • [42] Phase II study of CC-5013 in patients (pts) with metastatic renal cell cancer (MRCC)
    Rawat, A
    Needle, MN
    Miles, B
    Amato, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 403S - 403S
  • [43] Phase II dose escalation study of sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have had prior treatment with VEGFR-TKI antiangiogenic treatment
    Mancuso, A. P.
    De Paola, E. Donato
    Catalano, A.
    Calabro, F.
    Messina, C.
    Zivi, A.
    Cerbone, L.
    Vigna, L.
    Caristo, R.
    Sternberg, C. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [44] A phase II study of TKI258 in patients with castration-resistant prostate cancer (KCSG-GU11-05)
    Choi, Y. J.
    Kim, H. S.
    Park, S. H.
    Kim, B. S.
    Kim, K. H.
    Lee, H. J.
    Song, H. S.
    Shin, D. Y.
    Lee, H. Y.
    Kim, H-G.
    Lee, K. H.
    Lee, J-L.
    Park, K. H.
    ANNALS OF ONCOLOGY, 2016, 27
  • [45] Phase II study of bortezomib and thalidomide in patients with metastatic renal cell carcinoma (MRCC).
    Amato, R
    Misellati, A
    Marsh, L
    Shen, S
    Jac, J
    Ross, J
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9121S - 9122S
  • [46] Efficacy of VEGFR-TKI plus immune checkpoint inhibitor (ICI) in metastatic renal cell carcinoma (mRCC) patients with favorable IMDC prognosis.
    Ciccarese, Chiara
    Iacovelli, Roberto
    Bria, Emilio
    Schinzari, Giovanni
    Rossi, Ernesto
    Astore, Serena
    Cannella, Maria Antonella
    D'Angelo, Tatiana
    Cicala, Carlo Maria
    Maratta, Maria Grazia
    Tortora, Giampaolo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [47] Anlotinib in metastatic renal cell carcinoma (mRCC) with a previous anti-VEGFR TKI: Preliminary results from a multicenter, phase II trial.
    Zhou, Ai-Ping
    Bai, Yuxian
    Song, Van
    Li, Hangzhong
    Xie, Xiaodong
    Ren, Xiu-Bao
    Ye, Dingwei
    Liu, Jiyan
    Luo, Hong
    Bai, Xianzhong
    Qin, Shukui
    Fu, Cheng
    Wang, Jinwan
    Ma, Jianhui
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [48] Phase II study of lenalidomide in patients (pts.) with metastatic renal cell carcinoma (MRCC).
    Choueiri, T. K.
    Dreicer, R.
    Rini, B. I.
    Elson, P.
    Garcia, J.
    Mekhail, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 226S - 226S
  • [49] A multicenter, open-label, randomized phase 3 trial comparing the safety and efficacy of dovitinib (TKI258) versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapies
    Motzer, R.
    Sternberg, C. N.
    Vogelzang, N.
    Urbanowitz, G.
    Cai, C.
    Kay, A.
    Escudier, B.
    BJU INTERNATIONAL, 2012, 109 : 7 - 8
  • [50] Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma
    Mahoney, Kathleen M.
    Jacobus, Susanna
    Bhatt, Rupal S.
    Song, Jiaxi
    Carvo, Ingrid
    Cheng, Su-Chun
    Simpson, Mekailah
    Fay, Andre P.
    Puzanov, Igor
    Michaelson, M. Dror
    Atkins, Michael B.
    McDermott, David F.
    Signoretti, Sabina
    Choueiri, Toni K.
    CLINICAL GENITOURINARY CANCER, 2016, 14 (04) : 304 - +
12345